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Abstract
Background: Different forms of interferon alpha (IFN-a) have been used for several years in the treatment of chronic viral hepatitis type C 
(CVHC). Currently, pegylated forms of interferon alpha (PegIFN-a) in combination with ribavirin is the standard treatment. During therapy 
with IFN-a, side-effects occur, including thyroid diseases. The aim of this study was an evaluation of administered interferon’s impact on 
the frequency of autoimmune thyroiditis (ATI) occurrence among patients with CVH type C treated with INF-a and an assessment as to 
whether the type of interferon used is significant in ATI development. 
Material and methods: 149 patients aged 18–70 (mean 43.9 ± 2.3 years) with CVH type C participated in the study. The serum concen-
trations of thyrotrophin (TSH), free tyrosine (FT4), triiodothyronine (FT3), thyreoglobulin (Tg), antithyroid antibodies: antiperoxidase 
(TPOAb) and antithyreoglobulin (TgAb) were evaluated before, and after six and 12 months of treatment. Additionally, the thyroid 
echostructure was evaluated with ultrasonography. Sixty out of 149 patients received Peg-INF-a, and 89 patients were treated with 
recombinant IFN-a.
Results: ATI was confirmed in nine patients (6.04%) with CVH type C before the introduction of interferon. Seven of them underwent 
an exacerbation of hypothyroidsm during therapy with interferon. In 24 patients (17.14%), who did not have the signs of ATI at baseline, 
an elevated concentration of antithyroid antibodies was detected during therapy with interferon. The mean concentrations of TPOAb 
before, and after six and 12 months of treatment were, respectively: 12.4; 310.4 and 141.3 IU/ml, and the mean concentrations of TgAb 
were, respectively: 17.40; 108.0; and 125.6 IU/ml. After six months of treatment in this group of patients, 11 had hypothyroidsm and six had 
hyperthyroidsm. After 12 months of therapy, four patients had hypertthyroidsm and four showed signs and symptoms of hypothyroidsm; 
the remaining patients were in a euthyroid state. In ultrasound examination, reduction of echogenicity among patients with ATI before 
treatment was revealed in 75% of cases at baseline, in 83.3% after six months and in 100% after 12 months of treatment. In the group of 
patients presenting with ATI during IFN-a therapy, in which no disorders were found in initial examination, after six months of treatment 
a reduction of echogenicity was found in 69.2%, and after 12 months in 75%, of patients.
Conclusions: Among patients treated with interferon due to CVH type C, there is a risk of the development of ATI or the exacerbation of 
an existing one. There is no significant difference in ATI presentation in relation to the type of IFN-a used for treatment. 
(Pol J Endocrinol 2011; 62 (6): 517–522)
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Streszczenie
Wstęp: W leczeniu przewlekłego wirusowego zapalenia wątroby typu C (PWZWC) od kilkunastu lat stosuje się różne preparaty interferonu 
alfa (INF-a). Aktualnie standardem leczenia jest skojarzone zastosowanie pegylowanej formy interferonu alfa (PegINF-a) i rybawiryny. 
W trakcie leczenia INF-a występują działania niepożądane, wśród których znajdują się choroby tarczycy. Celem pracy jest ocena częstości 
występowania autoimmunologicznego zapalenia tarczycy (AZT) u pacjentów z PWZW C leczonych INF-a oraz ocena, czy na rozwój AZT 
ma wpływ rodzaj stosowanego INF.
Materiał i metody: W badaniu uczestniczyło 149 chorych z PWZW typu C w przedziale wieku 18–70 lat (średnia 43,9 ± 2,3 roku). U cho-
rych przed leczeniem oraz po 6 i 12 miesiącach leczenia oceniano stężenia w surowicy: tyreotropiny (TSH), wolnej tyroksyny (FT4), 
trijodotyroniny (FT3), tyreoglobuliny (Tg), przeciwciał przeciwtarczycowych: antyperoksydazowych (TPOAb) i antytyreoglobulinowych 
(TgAb). Dodatkowo oceniano echostrukturę tarczycy w USG. Wśród wszystkich 149 chorych u 60 stosowano pegylowany interferon alfa 
(PegINF-a), a u 89 INF-a.
Wyniki: U badanych chorych z PWZW C przed włączeniem interferonu AZT stwierdzono u 9 chorych (6,04%), wśród których u 7 nastąpiło 
zaostrzenie niedoczynności tarczycy w trakcie leczenia interferonem. U 24 chorych (17,14%), u których początkowo nie stwierdzano 
cech AZT, w trakcie leczenia INF wykazano podwyższone stężenia przeciwciał przeciwtarczycowych. Średnie stężenia TPOAb przed, po 
6 i 12 miesiącach leczenia wynosiły odpowiednio: 12,4; 310,4 i 141,3 IU/ml, a średnie stężenia TgAb odpowiednio: 17,40; 108,0 i 125,6 IU/ml. 
W tej grupie pacjentów po 6 miesiącach stwierdzono u 11 chorych hipertyreozę, a u 6 chorych hipotyreozę. Natomiast po 12 miesiącach 
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Introduction
Chronic viral hepatitis type B (CVHB) is caused by 
the HBV virus, while chronic viral hepatitis type C 
(CVHC) is caused by the HCV virus. The number of 
people chronically infected with the B and C viruses 
are respectively 350–400 million and about 170 million 
worldwide [1, 3]. About 500,000 people die every year 
due to complications of chronic HBV infection such 
as hepatic cirrhosis and hepatocellular carcinoma [2]. 
CVHC is a disease of slow progression: 20–30% of these 
patients within 10–20 years develop liver cirrhosis, and 
5% of them will subsequently develop hepatocellular 
carcinoma [3–5]. The risk of hepatocellular carcinoma 
increases among patients with established cirrhosis [3]. 
The aims of CVHC treatment are the elimination 
of the virus and inhibition of the disease develop-
ment, limitation of HCV infection spread, increase 
and prolongation of survival rate, and quality of life 
improvement [6, 7]. Currently, the standard CVHC 
treatment is the co-administration of PegINF-a together 
with ribavirin [8]. The mechanism of INF-a action is 
complex and based on antiviral, anti-proliferation and 
immunomodulatory effects [9, 10]. INF-a binds to the 
specific cell receptor that enhances target genes expres-
sion, which products cause: increase of class 1 major 
histocompatibility complex (MHC1) expression, increase 
of adhesive particles on effector cells count, increase 
of macrophages, NK cells and T lymphocytes activity 
and regulation of immunoglobulins production due 
to lymphocytes B activation [9–11]. The disadvantage 
of treatment with INF-a and ribavirin are frequently 
observed, and numerous, side effects [12]. It is assumed 
that INF-a is responsible for the occurrence of: fever, 
muscle and joint pain, sleeplessness, depression, thyroid 
function disorders, thrombocytopenia, leucopenia, hair 
loss, autoimmune haemolytic anaemia, psoriasis exac-
erbation and sarcoidosis development [9, 12]. Ribavirin, 
however, causes haemolysis, skin itching, skin rashes 
and cough [12].
Material and methods
The study included 149 patients aged 18–70 years, 82 men 
and 67 women. The average age was 43.9 ± 2.3 years. All 
patients were under the control of the Hepatology Out-
patient Department of the Westpomeranian Provincial 
Hospital in Szczecin between 2003 and 2007. All patients 
were checked for serum level of hormones: TSH, FT3, 
FT4 and for serum concentrations of antithyroid anti-
bodies: TPOAb, TgAb and thyroglobulin (Tg) to detect 
ATI at baseline and then after six and 12 months of 
treatment with INF-a.
Patients were divided into three groups:
 — Group 1 (116 patients) — without thyroid dysfunc-
tion before and during therapy with INF-a;
 — Group 2 (nine patients) — with ATI before the com-
mencement of therapy with INF-a;
 — Group 3 (24 patients) — who developed ATI during 
therapy with INF-a. 
The type of administered interferon was anal-
ysed among all patients in whom thyroid dysfunc-
tion occurred. In 60 out of 149 patients with CVHC, 
PegINF- a was used, while the remaining 89 had 
INF- a administered. Two patients from Group 2 were 
treated with PegINF-a, and the remaining seven pa-
tients with INF-a, whereas in Group 3, 12 patients were 
on PegINF-a and the other 12 on INF-a. Commercial 
kits by DPC Corporation were used to assay the serum 
level of TSH, FT3, FT4, TPOAb and TgAb. The labora-
tory tests were performed with Immulite unit in the 
Central Laboratory of the Westpomeranian Provincial 
Hospital in Szczecin. The criteria of diagnosing hyper-
thyroidism were, apart from the typical clinical symp-
toms, a decrease in TSH level < 0.4 mIU/ml (normal 
0.4–4.0 mIU/ml) and an increase of FT4 (normal range: 
0.8–1.9 ng/dl) and/or FT3 (normal range: 1.8–4.2 pg/ml). 
Subclinical hyperthyroidism was diagnosed in case 
of a decrease in TSH level and normal concentration 
of free thyroid hormones (TH). Hypothyroidism was 
diagnosed when the increased serum concentration of 
TSH and a decreased level of FT4 concentration were 
revealed (24). In a case of increased level of TSH within 
the limits of 5–10 mIU/ml and normal FT4 serum level, 
a latent hypothyroidism was diagnosed (24). ATI was 
diagnosed if an increased TPOAb level (normal range: 
0–35 IU/ml) and/or TgAb (normal: 0–40 IU/ml) were 
found. Increased concentrations of TPOAb and/or TgAb 
(level > 100 IU/ml) were set as a criterion of ATI diagno-
sis (24). Before the onset of treatment and after six and 
u 4 badanych odnotowano hipertyreozę i u 4 hipotyreozę; pozostali pacjenci byli w stanie eutyreozy. W badaniu USG obniżenie 
echogeniczności wśród pacjentów z AZT przed leczeniem stwierdzono u 75% w badaniu wstępnym, u 83,3% po 6 miesiącach oraz u 100% 
po 12 miesiącach leczenia. W grupie chorych z AZT w trakcie leczenia INF-a, u których w badaniu wstępnym nie wykryto żadnych zmian, 
po 6 miesiącach leczenia obniżenie echogeniczności stwierdzono u 69,2%, a po 12 miesiącach u 75%.
Wnioski: U chorych leczonych interferonem z powodu PWZW C istnieje ryzyko rozwoju świeżego lub nasilenia wcześniej występującego 
AZT. Rodzaj stosowanego INF-a nie wykazuje związku z występowaniem zaburzeń czynności gruczołu tarczowego. 
(Endokrynol Pol 2011; 62 (6): 517–522)
Słowa kluczowe: przewlekłe wirusowe zapalenie wątroby, interferon alfa, pegylowany interferon alfa, autoimmunologiczne zapalenie tarczycy
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12 months, the patients also had a thyroid ultrasound 
performed to evaluate its echogenicity.
In the statistical analysis of hormonal parameters, 
Statistica 60 Software was used. The data analysis began 
with verification of normal distribution hypothesis. For 
this purpose, the Lilliefors and Shapiro-Wilk tests were 
used. Hypothesis about the normal distribution was 
rejected because of asymmetry and too great a diversity 
of measurements. As a consequence, a non-parametric 
Kruskal-Wallis test was used for data analysis.
The protocol of the study was approved bt the Ethi-
cal Committee of the Pomeranian Medical University.
Results
Table I presents the median concentrations of thyro-
trophin, thyroxin, triiodothyronin, anti-peroxidase and 
antithyreoglobulin antibodies and thyreoglobulin in the 
examined groups of patients with CVHC.
Before the onset of therapy with INF-a, patients with 
ATI from Group 2 had the highest median TSH serum 
concentration. The median TSH serum concentration 
in Groups 2, 1 and 3 was 2.39 mIU/ml, 1.15 mIU/ml and 
1.115 mIU/ml, in that order. Within the FT3 level, the 
highest median was registered in Group 2, where it 
was 4.465 pg/ml, significantly higher than in Groups 3 
and 1, where it was 4.34 and 3.5 pg/ml respectively. The 
examined groups did not differ in respect to the median 
FT4 serum level before the onset of treatment with INF-
a. The results of Tg concentration show that patients 
from Group 2 were characterised by significantly lower 
median (2.595 ng/ml) compared to Group 1 (17.15 ng/ml) 
and Group 3 (10.29 ng/ml). Within the TGAb concentra-
tion in Group 2, the results significantly exceeded the 
normal range (median reaching 165 IU/ml). In the case 
of patients without and with thyroid function disorders 
after the beginning of therapy with INF-a, the baseline 
median value of TgAb serum concentration did not 
vary significantly and was within the normal range. An 
analogous situation was revealed in the case of TPOAb 
serum concentration median in the analysed groups of 
patients. After six months of therapy with IFN-a, a very 
high median TSH serum concentration was reached 
in Group 2 of 7.77 mIU/ml. Of the nine patients in this 
group, seven had hypothyroidism exacerbation. Six of 
them received INF-a and only one was on PegINF-a. 
In Group 3, 11 patients were diagnosed with hyper-
thyroidism; three of them were treated with PegINF-a, 
and the rest with INF-a. Six patients presented with 
hypothyroidism, of whom five received PegINF-a and 
one INF-a. The remaining patients were in a euthyroid 
state. The median of serum level of FT3 was the highest 
among patients in Group 3 compared to Groups 1 and 
2: 3.94 pg/ml, 3.2 pg/ml and 2.735 pg/ml, in that order. In 
the case of FT4 serum concentration, significantly lower 
median values were found in Group 2 than in Groups 1 
and 3: 0.82 ng/dl, 1.25 ng/dl and 1.27 ng/dl, in that order. 
In the range of serum Tg, the lowest median value was 
reached in Group 2, but the differences between the 
groups were not statistically significant. The most vis-
ible differences between the separate groups of patients 
were found in TgAb and TPOAb ranges. Significantly 
higher values were noted for Groups 2 and 3 compared 
to Group 1. In the case of TgAb, the median of concen-
trations for these groups were 280.5 IU/ml, 68.3 IU/ml 
and 20.0 IU/ml, respectively. Similarly, TPOAb values 
were 786.5IU/ml, 16.6 IU/ml and 10.0 IU/ml, respectively. 
After 12 months of therapy, the comparison examination 
of hormone levels still showed significantly different 
results for particular groups of patients. In the case of 
TSH, the highest value of median was reached in Group 
2 (4.67 mIU/ml). In this group, six patients maintained 
TSH serum concentration in the range typical for hy-
pothyroidism. Five of them had INF-a administered, 
and only one was on PegINF-a. 
None of the patients from Group 2 had the TSH 
concentration characteristic for hyperthyroidism. In 
the first and third groups, the TSH median values 
were significantly lower: 1.29 mIU/ml (Group 1) and 
2.25 mIU/ml (Group 3). In Group 3, after 12 months of 
therapy, the number of patients suffering from thyroid 
dysfunction decreased to four patients with hyper-
thyroidism and four with hypothyroidism. Also after 
12 months, the median FT3 and FT4 serum concentra-
tion values did not differ significantly in the studied 
groups. The median Tg serum level was significantly 
lower in Group 2 than in the other groups. Patients 
from Group 2 showed the highest TgAb and TPOAb 
serum concentrations, and the median of these antibod-
ies level were 266 IU/ml and 607 IU/ml, respectively. 
In Group 3, the values of serum concentration were 
significantly higher than in Group 1 and lower than 
in Group 2. The median of serum TgAb and TPOAb 
concentrations in patients from Group 3 were 106 IU/ml 
and 43.9 IU/ml, respectively, and in the patients from 
Group 2 — 20 IU/ml and 10 IU/ml, respectively. 
Table II presents the behaviour of thyroid echo-
genicity in the studied groups of patients before and 
during the treatment with interferon.
In thyroid ultrasound, decreased echogenicity in 
the group of patients with ATI before the therapy with 
INF-a was revealed in 75% of patents at baseline, in 
83.3% examined after six months, and in 100% examined 
after 12 months of therapy. However, in the group of 
patients in whom ATI developed during the interferon 
treatment, decreased echogenicity was initially found 
only in 7.7% of them, while after six months of therapy 
the decrease of echogenicity was already diagnosed 
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in 69.2%, and after 12 months in 75% of patients. De-
creased thyroid echostructure was also observed in 
Group 1, i.e. patients without ATI before and during 
treatment with interferon.
Table I. Median of thyrotrophin, thyroxin, triiodothyronin, anti-thyroid antibodies and thyroglobulin concentrations in 
examined groups of patients with CVH
Tabela I. Mediana stężeń w surowicy tyreotropiny, hormonów tarczycowych, przeciwciał przeciwtarczycowych i tyreoglobuliny 
w badanych grupach chorych z PWZW C
Parameters and time of examination Group 1 Group 2 Group 3 Kruskal-Wallis test
TSH
At baseline
Median 1.15 *(2) 2.39 *(1.3) 1.115 *(2)
p = 0.0244
Min–Max 0.42–3.85 0.61–12.2 0.411–3.67
6m
Median 1.2 *(2) 7.77 *(1.3) 0.814 *(2)
p = 0.0000
Min–Max 0.406–4.0 3.91–75 0.002–74.6
12m
Median 1.29 *(2) 4.675 *(1) 2.25
p = 0.0007
Min–Max 0.403–3.94 1.08–8.98 0.016–11
FT3
At baseline
Median 3.5 *(2) 4.465 *(1) 4.34
p = 0.0015
Min–Max 1.81–4.2 4.1–5.03 2.01–4.19
6m
Median 3.2 *(3) 2.735 *(3) 3.94 *(1.2)
p = 0.0049
Min–Max 1.8–4.19 2.22–3.34 2.11–6.06
12m
Median 3.39 3.215 4.04
p = 0.1534
Min–Max 2.11–4.19 1.99–4.07 1.31–6.64
FT4
At baseline
Median 1.27 1.205 1.245
p = 0.6239
Min–Max 0.83–1.85 0.8–1.43 1–1.54
6m
Median 1.25 *(2) 0.82 *(1.3) 1.27 *(2)
p = 0.0517
Min–Max 0.8–1.85 0.45–1.31 0.44–2.6
12m
Median 1.23 1.095 1.265
p = 0.6053
Min–Max 0.8–1.69 0.99–1.79 0.55–3.38
Tg
At baseline
Median 17.15 *(2.3) 2.595*(1.3) 10.29 *(1.2)
p = 0.0229
Min–Max 0.5–53.7 0.81–84.4 0.91–52.7
6m
Median 17.85 1.4 38.2
p = 0.0864
Min–Max 3.8–54.7 0.5–139 0.84–349
12m
Median 16.5 *(2) 0.5 *(1) 16.1
p = 0.0165
Min–Max 0.5–55 0.5–48 0.2–160
TgAb
At baseline
Median 20 *(2.3) 165 *(1.3) 18 *(1.2)
p = 0.0000
Min–Max 7.2–31 20–259 10–33.7
6m
Median 20 *(2.3) 280.5 *(1.3) 68.3 *(1.2)
p = 0.0000
Min–Max 3.04–37.5 170–2052 18.5–873
12m
Median 20 *(2.3) 266 *(1.3) 106 *(1.2)
p = 0.0000
Min–Max 12–40 37.7–1166 20–362
TPOAb
At baseline 
Median 10 *(2) 252 *(1.3) 10 *(2)
p = 0.0000
Min–Max 5.0–34.6 51.7–468 4.2–34.3
6m
Median 10 *(2.3) 786.5 *(1.3) 16.6 *(1.2)
p = 0.0000
Min–Max 2.08–32.7 40.6–2500 5–4181
12m
Median 10 *(2.3) 607 *(1.3) 43.9 *(1.2)
p = 0.0000
Min–Max 5,1-35 42-1952 10-441
Note: statistically significant results are marked with an asterisk; a group in which the statistically significant difference occurred is written in brackets. 
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Discussion
Chronic viral hepatitis type B and C are diseases 
that have a progressive course which may lead to 
liver cirrhosis and hepatocellular carcinoma [13]. About 
300–400 million people are chronically infected with 
HBV, despite the effective prophylaxis, passive and 
active, that has been available for more than 25 years 
around the world [13]. Infection with HCV concerns 
about 2% of the human population, meaning that in 
Poland 400,000-700,000 people could be affected [13]. 
The HCV virus infection, because of its widespread 
prevalence and progressive nature, is the major cause 
of end-stage liver disease worldwide [8]. 
Currently, the standard treatment of CVHC is co-ad-
ministration of alpha interferon with ribavirin [3]. Dur-
ing the therapy with interferon, mostly transient side 
effects occur, such as clinically manifested autoimmune 
diseases or the presence of antibodies against many 
tissues and organs without clinical symptoms. Usually, 
the autoaggressive diseases concern the thyroid gland 
[14]. Antithyroid antibodies production is a result of 
improper class II histocompatibility antigens expression 
on the thyreocytes surface and a direct cytotoxic action 
of lymphocytes T on thyroid cells [14]. In our own mate-
rial, ATI was revealed in nine (6.04%) out of 149 patients 
with CVHC before the IFN therapy onset. A similar 
percentage with increased antithyroid antibodies serum 
concentration among patients with CVHC has been 
described by Pawlotsky et al. who found an increased 
concentration of antibodies in five out of 61 patients 
—7% of the studied group [15], whereas Marcellin et 
al. showed an increased concentration of antithyroid 
antibodies in only 3% out of 86 patients with CVHC 
[16]. The frequency of increased antithyroid antibodies 
concentrations without the clinical thyroid disorders 
among patients with CVHC depends in large measure 
on geographical factors, gender and age [16]. Similar 
results are found in patients with normal thyroid func-
tion without CVHC. Pearce et al. confirmed an elevated 
level of antithyroid antibodies in 10% of the general 
population in the United States; but in women over 60, 
the increased antibodies level was found in as many as 
25% of the researched population [17]. In our study, 
of the nine patients with ATI diagnosed before IFN 
treatment, hypothyroiditis exacerbation was detected 
in seven of them. Tran et al. in a study of 72 patients, 
29 women and 43 men, diagnosed an elevated concen-
tration of antithyroid antibodies concentration in nine 
women (31%). In only six of them (20.7%) was the level 
very high, and two patients had clinical symptoms of 
hypothyroidism. During 12 months of therapy with 
INF-a, one patient had a significant increase of anti-
bodies, while in three patients, another exacerbation of 
hypothyroidism occurred [18].
In our study group, in 24 patients (17.14%) who ini-
tially did not demonstrate any features of autoimmune 
process, an increased level of antithyroid antibodies 
was found during the therapy with interferon. In this 
group after six months of treatment, hyperthyroidism 
was diagnosed in 11 patients, whereas six of them had 
hypothyroidism. After 12 months of therapy with inter-
feron in this group, four patients had hyperthyroidism 
(in one of them it was a newly developed abnormality), 
one patient moved from hypothyroidism into hyper-
thyroidism, in two patients there was a continuation 
of hyperthyroidism, four patients continued with 
hypothyreosis and the remaining patients were in 
a euthyreoid state. In the study by Watanabe et al [9], 
nine out of 106 patients with normal thyroid function 
before treatment with INF-a (six women and three 
men) developed thyroid function disorders during the 
treatment. In six of them, hyperthyroidism was revealed 
after 16–30 weeks of therapy, and in the remaining three, 
hypothyroidism occurred 8–23 weeks after the therapy 
with INF-a had begun. In another study by Marazu-
ela et al. [19], 14.8% of women and only 1% of men 
without ATI features before the therapy with INF-a, 
showed thyroid function disorders during the therapy. 
After six months of treatment with INF-a, one patient 
underwent a clinical transition from hypothyreoidism 
into hyperthyreoidism and the return of euthyreoidism 
after the end of therapy. The reports concerning the 
occurrence of thyroid dysfunctions during INF-a are 
inconclusive. According to Monzani et al. [20], such 
thyroid gland function disorders are confirmed in 6.2% 
of patients, more often hypothyroidism than hyperthy-
roidism (3.9% and 2.3%, respectively), while symptoms 
of hyperthyroidism develop earlier than symptoms of 
hypothyroidism during the therapy with interferon. 
Other research has concluded that 12–15% of patients 
suffer from thyroid functions disorders during the 
therapy [21, 23], and an increased level of antithyroid 
antibodies can be found in as many as 17–40% of patients 
treated with interferon [22, 23]. For autoimmune thyroid 
diseases, the hypoechogenic thyroid image in ultra-
Table II. Percentage of patients with a decreased thyroid 
echogenicity
Tabela II. Odsetek pacjentów z obniżoną echogenicznością 
tarczycy
Time of examination Group 1 Group 2 Group 3
At baseline 14.7% 75.0% 7.7%
After 6 months 18.0% 83.3% 69.2%
After 12 months 22.5% 100% 75.0%
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sound examination is characteristic. Decreased echo-
genicity of thyroid gland is found in 80% of patients 
suffering from Graves disease and in 18–77% with 
Hashimoto’s disease [24]. 
In our study, the echogenicity decrease among pa-
tients with ATI before interferon treatment was found 
in 75% in initial examination, in 83.3% in the examina-
tion after six months, and in 100% in the examination 
after 12 months, whereas in the group of patients who 
developed ATI during interferon treatment, 53.8% 
showed no alterations in the initial examination, after 
six months of treatment decreased echogenicity was 
revealed in 69.2%, and after 12 months in 75% of pa-
tients. Similarly, other authors have found changes in 
echogenicity during treatment with interferon, espe-
cially at significantly increased concentrations of serum 
antithyroid antibodies [23].
Conclusions
Therapy with interferon alpha in patients with chronic 
viral hepatitis bears a risk of autoimmune thyroiditis 
development or the exacerbation of a pre-existing 
inflammation in the thyroid gland, with the clinical 
presentation of hyperthyroidism as well as of hy-
pothyroidism. 
Patients with chronic viral hepatitis subjected to 
therapy with interferon should have their serum levels 
of thyrotrophin, thyroxin, triiodothyronin and antithy-
roid antibodies measured at baseline and regularly 
monitored during therapy. Those with pre-existing ATI 
should be checked more frequently because hyperthy-
roidism as well as hypothyroidism may develop, and 
one dysfunction can transit into the other.
The type of interferon administered is not associated 
with the frequency or the pattern of thyroid gland 
function. 
Ultrasound thyroid examination in patients with 
chronic viral hepatitis is helpful in recognising and 
monitoring autoimmune thyroiditis during therapy 
with interferon.
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